603998 方盛制药
午间休市 12-08 11:29:54
资讯
新帖
简况
6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选
智通财经网 · 11:31
6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选
方盛制药:12月3日接受机构调研,西部证券参与
证券之星 · 12-05 17:51
方盛制药:12月3日接受机构调研,西部证券参与
方盛制药:11月19日接受机构调研,中信建投参与
证券之星 · 11-24
方盛制药:11月19日接受机构调研,中信建投参与
每周股票复盘:方盛制药(603998)吲哚布芬片获生产批准
证券之星 · 11-16
每周股票复盘:方盛制药(603998)吲哚布芬片获生产批准
方盛制药(603998.SH):吲哚布芬片获得《药品注册证书》
智通财经 · 11-11
方盛制药(603998.SH):吲哚布芬片获得《药品注册证书》
【机构调研记录】南方基金调研方盛制药、思瑞浦等4只个股(附名单)
证券之星 · 11-10
【机构调研记录】南方基金调研方盛制药、思瑞浦等4只个股(附名单)
股市必读:方盛制药(603998)11月7日披露最新机构调研信息
证券之星 · 11-10
股市必读:方盛制药(603998)11月7日披露最新机构调研信息
每周股票复盘:方盛制药(603998)小儿荆杏止咳颗粒新增覆盖320家医疗机构
证券之星 · 11-09
每周股票复盘:方盛制药(603998)小儿荆杏止咳颗粒新增覆盖320家医疗机构
方盛制药:11月5日接受机构调研,天风证券、南方基金等多家机构参与
证券之星 · 11-07
方盛制药:11月5日接受机构调研,天风证券、南方基金等多家机构参与
每周股票复盘:方盛制药(603998)Q3营收下滑因集采及商业资产出表
证券之星 · 11-02
每周股票复盘:方盛制药(603998)Q3营收下滑因集采及商业资产出表
【机构调研记录】弘毅远方基金调研方盛制药
证券之星 · 10-28
【机构调研记录】弘毅远方基金调研方盛制药
【机构调研记录】光大保德信基金调研神工股份、方盛制药等3只个股(附名单)
证券之星 · 10-28
【机构调研记录】光大保德信基金调研神工股份、方盛制药等3只个股(附名单)
方盛制药(603998)披露2025年第三季度业绩说明会召开情况,10月27日股价上涨1.32%
证券之星 · 10-27
方盛制药(603998)披露2025年第三季度业绩说明会召开情况,10月27日股价上涨1.32%
每周股票复盘:方盛制药(603998)Q3净利增17.6%,股东户数降6.5%
证券之星 · 10-26
每周股票复盘:方盛制药(603998)Q3净利增17.6%,股东户数降6.5%
方盛制药(603998)2025年三季报简析:净利润同比增长17.6%
证券之星 · 10-25
方盛制药(603998)2025年三季报简析:净利润同比增长17.6%
方盛制药:控股股东张庆华解除质押3158万股
每日经济新闻 · 10-23
方盛制药:控股股东张庆华解除质押3158万股
方盛制药最新公告:前三季度净利润同比增长17.60%
证券之星 · 10-23
方盛制药最新公告:前三季度净利润同比增长17.60%
方盛制药(603998)披露公司《药品生产许可证》变更公告,10月21日股价上涨0.81%
证券之星 · 10-21
方盛制药(603998)披露公司《药品生产许可证》变更公告,10月21日股价上涨0.81%
每周股票复盘:方盛制药(603998)养血祛风止痛颗粒获批上市
证券之星 · 10-19
每周股票复盘:方盛制药(603998)养血祛风止痛颗粒获批上市
【私募调研记录】敦和资管调研方盛制药
证券之星 · 10-16
【私募调研记录】敦和资管调研方盛制药
暂无数据
公司概况
公司名称:
湖南方盛制药股份有限公司
所属行业:
医药制造业
上市日期:
2014-12-05
主营业务:
湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是藤黄健骨片、强力枇杷膏(蜜炼)/露、依折麦布片、玄七健骨片、小儿荆杏止咳颗粒、血塞通分散片/片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊、蒲地蓝消炎片。公司先后获评国家火炬计划重点高新技术企业、国家级守合同重信用企业、国家博士后科研工作站、国家认定企业技术中心、国家技术创新示范企业、国家知识产权示范企业、2024年度中国中药研发实力50强、湖南省省长质量奖企业、湖南省绿色工厂、湖南省示范性医药企业、湖南省小巨人计划企业、湖南省质量信用AAA级企业、湖南省心脑血管药物工程技术研究中心、湖南省工业品牌培育示范企业、湖南省产教融合型企业、湖南省疫情防控突出贡献企业、湖南省节水型企业、2022-2023年度中国医药制药业百强、2022-2023年度中国医药行业守法诚信企业、2025年入选湖南省“数字新基建”100个标志性项目、2025年获“国家级绿色工厂”称号。
发行价格:
14.85
{"stockData":{"symbol":"603998","market":"SH","secType":"STK","nameCN":"方盛制药","latestPrice":11.59,"timestamp":1765164594000,"preClose":11.48,"halted":0,"volume":8157779,"delay":0,"changeRate":0.0096,"floatShares":438999999,"shares":438999999,"eps":0.6727,"marketStatus":"午间休市","change":0.11,"latestTime":"12-08 11:29:54","open":11.56,"high":11.96,"low":11.55,"amount":95718000,"amplitude":0.0357,"askPrice":11.59,"askSize":60,"bidPrice":11.58,"bidSize":293,"shortable":0,"etf":0,"ttmEps":0.6727,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765170000000},"marketStatusCode":3,"adr":0,"adjPreClose":11.48,"symbolType":"stock","openAndCloseTimeList":[[1765157400000,1765164600000],[1765170000000,1765177200000]],"highLimit":12.63,"lowLimit":10.33,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":439081360,"isCdr":false,"pbRate":3.01,"roa":"--","peRate":17.229077,"roe":"15.71%","epsLYR":0.59,"committee":0.556286,"marketValue":5089000000,"turnoverRate":0.0186,"status":0,"floatMarketCap":5089000000},"requestUrl":"/m/hq/s/603998/tweets","defaultTab":"tweets","newsList":[{"id":"2589803385","title":"6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2589803385","media":"智通财经网","labels":["shareholding"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589803385?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:31","pubTimestamp":1765164685,"startTime":"0","endTime":"0","summary":"根据国家医保局披露的名单,此次新增的6个中成药品种分别为:温阳解毒颗粒、参郁宁神片、养血祛风止痛颗粒、益气清肺颗粒、玉女煎颗粒、芪防鼻通片,其中包括3个1.1类新药,3个3类新药。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0185","BK0183","002603","BK0046","BK0097","BK0028","603998","600557","BK0196","BK0060","BK0042","BK0239","BK0012","BK0175","000999","BK0188","BK0010"],"gpt_icon":0},{"id":"2589189535","title":"方盛制药:12月3日接受机构调研,西部证券参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2589189535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589189535?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:51","pubTimestamp":1764928285,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年12月5日方盛制药发布公告称公司于2025年12月3日接受机构调研,西部证券参与。方盛制药2025年三季报显示,前三季度公司主营收入12.53亿元,同比下降7.02%;归母净利润2.68亿元,同比上升17.6%;扣非净利润2.13亿元,同比上升30.54%;其中2025年第三季度,公司单季度主营收入4.19亿元,同比下降4.26%;单季度归母净利润9904.46万元,同比上升8.49%;单季度扣非净利润7120.39万元,同比上升36.37%;负债率42.2%,投资收益224.18万元,财务费用878.85万元,毛利率71.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500028078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0060","BK0188","BK0028","BK0276","002673","BK0239","603998"],"gpt_icon":0},{"id":"2585463818","title":"方盛制药:11月19日接受机构调研,中信建投参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2585463818","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585463818?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:01","pubTimestamp":1763978516,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年11月24日方盛制药发布公告称公司于2025年11月19日接受机构调研,中信建投参与。方盛制药2025年三季报显示,前三季度公司主营收入12.53亿元,同比下降7.02%;归母净利润2.68亿元,同比上升17.6%;扣非净利润2.13亿元,同比上升30.54%;其中2025年第三季度,公司单季度主营收入4.19亿元,同比下降4.26%;单季度归母净利润9904.46万元,同比上升8.49%;单季度扣非净利润7120.39万元,同比上升36.37%;负债率42.2%,投资收益224.18万元,财务费用878.85万元,毛利率71.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","601066","BK0276","603998","BK0239"],"gpt_icon":0},{"id":"2583519196","title":"每周股票复盘:方盛制药(603998)吲哚布芬片获生产批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583519196","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583519196?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:35","pubTimestamp":1763235315,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,方盛制药报收于13.01元,较上周的11.98元上涨8.6%。本周,方盛制药11月14日盘中最高价报13.5元,股价触及近一年最高点。方盛制药当前最新总市值57.12亿元,在中药板块市值排名42/67,在两市A股市值排名3057/5165。吲哚布芬片主要用于动脉硬化引起的缺血性心血管病变、缺血性脑血管病变、静脉血栓形成及血液透析时预防血栓形成。截至目前,公司对该药品的研发投入累计约2,872万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"gpt_icon":0},{"id":"2582935626","title":"方盛制药(603998.SH):吲哚布芬片获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2582935626","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582935626?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:22","pubTimestamp":1762849334,"startTime":"0","endTime":"0","summary":"智通财经APP讯,方盛制药(603998.SH)发布公告,近日,公司收到国家药品监督管理局(简称“国家药监局”)核准签发的《药品注册证书》,公司研发的吲哚布芬片已获得药品批准文号,并可进行生产。吲哚布芬是一种异吲哚啉基丁酸衍生物,为一种血小板聚集的抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"方盛制药(603998.SH):吲哚布芬片获得《药品注册证书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0060","603998"],"gpt_icon":0},{"id":"2582581199","title":"【机构调研记录】南方基金调研方盛制药、思瑞浦等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582581199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582581199?lang=zh_cn&edition=full","pubTime":"2025-11-10 08:01","pubTimestamp":1762732884,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月7日披露的机构调研信息,南方基金近期对4家上市公司进行了调研,相关名单如下:1)方盛制药 调研纪要:公司通过加强学术推广、深化医院准入和品牌建设应对呼吸类产品阶段性下滑,小儿荆杏止咳颗粒和强力枇杷膏覆盖医疗机构持续扩展。旗下最近一年表现最佳的公募基金产品为南方碳中和股票发起A,最新单位净值为1.45,近一年增长71.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000001528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SGXZ81163826.USD","BK0060","BK0231","603998","SGXZ49509284.SGD","BK0239","688536"],"gpt_icon":0},{"id":"2582818573","title":"股市必读:方盛制药(603998)11月7日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2582818573","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582818573?lang=zh_cn&edition=full","pubTime":"2025-11-10 01:50","pubTimestamp":1762710621,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,方盛制药报收于11.98元,上涨1.61%,换手率3.27%,成交量14.34万手,成交额1.72亿元。机构调研要点公司表示,受季节性因素影响,呼吸类产品销售额出现阶段性下降。未来将通过布局有门槛的仿制药、加快中药创新药上市、加强品种储备应对降价趋势,把握市场重构机遇。2025年前三季度,中药创新药妇科止血消痛颗粒获国家药监局临床试验批准;蛭龙通络片完成Ⅱ期临床并取得报告;化药仿制药瑞卢戈利片于2025年10月15日获批临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000000722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"gpt_icon":0},{"id":"2582869706","title":"每周股票复盘:方盛制药(603998)小儿荆杏止咳颗粒新增覆盖320家医疗机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2582869706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582869706?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:14","pubTimestamp":1762629254,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,方盛制药报收于11.98元,较上周的12.29元下跌2.52%。本周关注点来自机构调研要点:小儿荆杏止咳颗粒新增覆盖公立医疗机构超过320家,累计覆盖近2,000家。2025年前三季度,公司在止咳类产品市场拓展方面取得显著进展,小儿荆杏止咳颗粒新增覆盖公立医疗机构超过320家,累计覆盖近2,000家,其中等级医院超过1,200家;同时,该产品新增成人适应症研究进展顺利,二期临床试验已完成,三期临床研究正在有序推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"gpt_icon":0},{"id":"2581003885","title":"方盛制药:11月5日接受机构调研,天风证券、南方基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2581003885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581003885?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:33","pubTimestamp":1762508039,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年11月7日方盛制药发布公告称公司于2025年11月5日接受机构调研,天风证券、南方基金、光证资管参与。这个矩阵将以中药创新药为核心,同时以其他经典中成药、高端仿制药和复杂制剂为补充,形成多元化的产品组合,确保公司业绩的稳健增长。该股最近90天内共有6家机构给出评级,买入评级6家;过去90天内机构目标均价为14.81。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700028196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0276","BK0060","601162"],"gpt_icon":0},{"id":"2580479477","title":"每周股票复盘:方盛制药(603998)Q3营收下滑因集采及商业资产出表","url":"https://stock-news.laohu8.com/highlight/detail?id=2580479477","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580479477?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:35","pubTimestamp":1762029312,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,方盛制药报收于12.29元,较上周的12.13元上涨1.32%。本周,方盛制药10月29日盘中最高价报12.77元。本周关注点来自业绩披露要点:公司第三季度营业收入下降主要受药品集采、呼吸系统药销售下滑及医药商业收入大幅减少影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998"],"gpt_icon":0},{"id":"2578084926","title":"【机构调研记录】弘毅远方基金调研方盛制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2578084926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578084926?lang=zh_cn&edition=full","pubTime":"2025-10-28 08:05","pubTimestamp":1761609952,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及10月27日披露的机构调研信息,弘毅远方基金近期对1家上市公司进行了调研,相关名单如下:1)方盛制药 调研纪要:公司核心业务板块保持稳健发展态势。弘毅远方基金成立于2018年,截至目前,资产管理规模6.64亿元,排名181/210;资产管理规模6.63亿元,排名160/210;管理公募基金数14只,排名146/210;旗下公募基金经理4人,排名157/210。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800009045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"gpt_icon":0},{"id":"2578608176","title":"【机构调研记录】光大保德信基金调研神工股份、方盛制药等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578608176","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578608176?lang=zh_cn&edition=full","pubTime":"2025-10-28 08:05","pubTimestamp":1761609908,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及10月27日披露的机构调研信息,光大保德信基金近期对3家上市公司进行了调研,相关名单如下:1)神工股份 调研纪要:公司硅零部件用于存储芯片刻蚀工艺,消耗量随开工率提升而增加,受益于国产替代及海外技术限制,市场机会显现。2)方盛制药 调研纪要:公司核心业务板块保持稳健发展态势。在心脑血管和骨骼肌肉系统用药领域,主力产品销量持续攀升,市场份额稳步提高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800008997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0214","BK0060","BK0235","688233","BK0239"],"gpt_icon":0},{"id":"2578061130","title":"方盛制药(603998)披露2025年第三季度业绩说明会召开情况,10月27日股价上涨1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578061130","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578061130?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:46","pubTimestamp":1761558374,"startTime":"0","endTime":"0","summary":"截至2025年10月27日收盘,方盛制药报收于12.29元,较前一交易日上涨1.32%,最新总市值为53.96亿元。公司近日披露了关于2025年第三季度业绩说明会召开情况的公告。公告显示,湖南方盛制药股份有限公司于2025年10月24日召开2025年第三季度业绩说明会,董事长兼总经理周晓莉、独立董事袁雄、财务总监曹湘琦、董事会秘书何仕出席。针对呼吸系统用药收入下降问题,公司表示小儿荆杏止咳颗粒累计覆盖近2000家公立医疗机构,强力枇杷膏累计覆盖近11000家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700025103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"gpt_icon":0},{"id":"2578501166","title":"每周股票复盘:方盛制药(603998)Q3净利增17.6%,股东户数降6.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578501166","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578501166?lang=zh_cn&edition=full","pubTime":"2025-10-26 01:46","pubTimestamp":1761414370,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,方盛制药报收于12.13元,较上周的12.19元下跌0.49%。本周,方盛制药10月21日盘中最高价报12.45元。股本股东变化截至2025年9月30日,方盛制药股东户数为30,993户,较6月30日减少2,156户,减幅6.5%。户均持股数量由1.32万股增至1.42万股,户均持股市值为16.96万元。全资子公司广东方盛健盟药业有限公司瑞卢戈利片获临床试验批准通知书。控股股东张庆华于2025年10月23日解除质押3,158万股,占其持股20.24%,当前累计质押股份占其持股比例降至44.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"gpt_icon":0},{"id":"2578525928","title":"方盛制药(603998)2025年三季报简析:净利润同比增长17.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578525928","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578525928?lang=zh_cn&edition=full","pubTime":"2025-10-25 06:03","pubTimestamp":1761343423,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期方盛制药发布2025年三季报。根据财报显示,方盛制药净利润同比增长17.6%。截至本报告期末,公司营业总收入12.53亿元,同比下降7.02%,归母净利润2.68亿元,同比上升17.6%。按单季度数据看,第三季度营业总收入4.19亿元,同比下降4.26%,第三季度归母净利润9904.46万元,同比上升8.49%。去年的净利率为14.06%,算上全部成本后,公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998"],"gpt_icon":0},{"id":"2577305264","title":"方盛制药:控股股东张庆华解除质押3158万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2577305264","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577305264?lang=zh_cn&edition=full","pubTime":"2025-10-23 19:01","pubTimestamp":1761217260,"startTime":"0","endTime":"0","summary":"每经AI快讯,10月23日,方盛制药公告,控股股东张庆华于2025年10月23日解除质押3158万股公司股份,占公司总股本的7.19%。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-10-23/doc-infuwsqk9351660.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-23/doc-infuwsqk9351660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603998","BK0060","BK0239"],"gpt_icon":0},{"id":"2577377033","title":"方盛制药最新公告:前三季度净利润同比增长17.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577377033","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577377033?lang=zh_cn&edition=full","pubTime":"2025-10-23 18:09","pubTimestamp":1761214196,"startTime":"0","endTime":"0","summary":"方盛制药(603998.SH)公告称,方盛制药(603998.SH)发布2025年第三季度报告,第三季度营收为4.19亿元,同比下降4.26%;归属于上市公司股东的净利润为9904.46万元,同比增长8.49%。前三季度实现营业收入12.53亿元,同比下降7.02%;归属于上市公司股东的净利润为2.68亿元,同比增长17.60%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300030451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998"],"gpt_icon":0},{"id":"2577879716","title":"方盛制药(603998)披露公司《药品生产许可证》变更公告,10月21日股价上涨0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577879716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577879716?lang=zh_cn&edition=full","pubTime":"2025-10-21 22:21","pubTimestamp":1761056474,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘,方盛制药报收于12.4元,较前一交易日上涨0.81%,最新总市值为54.45亿元。该股当日开盘12.35元,最高12.45元,最低12.23元,成交额达1.68亿元,换手率为3.1%。近日,方盛制药发布关于公司《药品生产许可证》变更的公告。公司表示,本次变更不影响现有生产结构,不构成重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100037029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"gpt_icon":0},{"id":"2576046821","title":"每周股票复盘:方盛制药(603998)养血祛风止痛颗粒获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2576046821","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576046821?lang=zh_cn&edition=full","pubTime":"2025-10-19 02:36","pubTimestamp":1760812571,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘,方盛制药报收于12.19元,较上周的11.89元上涨2.52%。本周,方盛制药10月16日盘中最高价报12.63元。2025年上半年,子公司方盛健盟中药创新药养血祛风止痛颗粒获国家药监局核准签发的《药品注册证书》。2023年全球销售额达29,957万美元,同比增长58.6%。本次质押后,张庆华先生累计质押股份100,905,200股,占其所持股份64.67%,占公司总股本22.98%。张庆华及其一致行动人合计持有公司股份165,574,607股,合计质押股份占其持股总数的60.94%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"gpt_icon":0},{"id":"2575763060","title":"【私募调研记录】敦和资管调研方盛制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2575763060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575763060?lang=zh_cn&edition=full","pubTime":"2025-10-16 08:03","pubTimestamp":1760573013,"startTime":"0","endTime":"0","summary":"根据市场公开信息及10月15日披露的机构调研信息,知名私募敦和资管近期对1家上市公司进行了调研,相关名单如下:1)方盛制药 调研纪要:公司2025年第三季度核心品种销售稳健增长,但呼吸类药品收入同比下降。围绕建立\"一切以客户为中心\"的一流资产管理机构发展目标,敦和资管已经建立并形成了包括投研、系统建设、市场销售、合规风控、人力资源和财务支持的前中后台全面保障运营体系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025101600005118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765169971754,"stockEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0246},{"period":"3month","weight":0.0288},{"period":"6month","weight":0.1318},{"period":"1year","weight":0.0755},{"period":"ytd","weight":0.1457}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南方盛制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30993人(较上一季度减少6.50%)","perCapita":"14167股","listingDate":"2014-12-05","address":"湖南省长沙市岳麓区高新区麓松路789号","registeredCapital":"43908万元","survey":" 湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是藤黄健骨片、强力枇杷膏(蜜炼)/露、依折麦布片、玄七健骨片、小儿荆杏止咳颗粒、血塞通分散片/片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊、蒲地蓝消炎片。公司先后获评国家火炬计划重点高新技术企业、国家级守合同重信用企业、国家博士后科研工作站、国家认定企业技术中心、国家技术创新示范企业、国家知识产权示范企业、2024年度中国中药研发实力50强、湖南省省长质量奖企业、湖南省绿色工厂、湖南省示范性医药企业、湖南省小巨人计划企业、湖南省质量信用AAA级企业、湖南省心脑血管药物工程技术研究中心、湖南省工业品牌培育示范企业、湖南省产教融合型企业、湖南省疫情防控突出贡献企业、湖南省节水型企业、2022-2023年度中国医药制药业百强、2022-2023年度中国医药行业守法诚信企业、2025年入选湖南省“数字新基建”100个标志性项目、2025年获“国家级绿色工厂”称号。","listedPrice":14.85},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"方盛制药,603998,方盛制药股票,方盛制药股票老虎,方盛制药股票老虎国际,方盛制药行情,方盛制药股票行情,方盛制药股价,方盛制药股市,方盛制药股票价格,方盛制药股票交易,方盛制药股票购买,方盛制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}